Fabio Luiz de Menezes Montenegro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fabio Luiz de Menezes Montenegro has a total of 225 co-authors. Here are the top co-authors by number of shared publications:
- Marilia D'ELboux Guimarães Brescia
Divisão de Cirurgia de Cabeça e Pescoço, Unidade de Paratireoide, LIM-28, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brasil
13 shared publications - Delmar Muniz Lourenço
Endocrine Genetics Unit, Laboratory of Cellular and Molecular Endocrinology (LIM-25), Division of Endocrinology and Metabolism, Hospital das Clinicas (HCFMUSP), University of São Paulo School of Medicine (FMUSP), Faculdade de Medicina da Universidade de São Paulo (FMUSP)
11 shared publications - Marcos Roberto Tavares
Departamento de Cirurgia, Disciplina de Cirurgia de Cabeça e Pescoço, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil
10 shared publications - Vanda Jorgetti
Universidade de São Paulo, Brazil
10 shared publications - Rodrigo Almeida Toledo
Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
8 shared publications - Rosa Maria Affonso Moysés
LIM 16 do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
8 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 70 (5) , 1-8
Prognostic factors and survival in parathyroid carcinoma: a 50-year single-center cohort study
Objective: This study aims to analyze the clinical characteristics and prognostic factors of patients with parathyroid carcinoma (PC) treated at a tertiary institution. Subjects and methods: This retrospective cohort included 30 patients with PC who were treated between 1970 and 2023 at a single reference center. Clinical, pathological, and survival data were reviewed and prognostic factors were evaluated. Results: Of the 30 cases, 16 (53.3%) were women. Mean age at diagnosis was 45.9 years, median follow-up was 60 months and mean tumor size was 33 mm. Median follow-up was 60 months. Disease recurrence occurred in 16 (53.3%) cases, with disease persistence in three (10.0%). Median disease-free survival was 80 months, with a 57% overall survival rate. Neither gender nor age showed significant impact on survival. Patients with lower-stage tumors (T1 by the AJCC/UICC and T1+T2 by the Shaha classification) had significantly better overall survival (p = 0.004 and p = 0.0018, respectively) and disease-free survival (p = 0.03 and p = 0.04, respectively) than those with more advanced stages (p = 0.03 and p = 0.04, respectively). Additionally, patients who experienced tumor recurrence after 36 months had significantly better survival outcomes than those with earlier recurrences (p = 0.02). Conclusion: Advanced tumor stage (T3 by the Shaha or T2 and above by the AJCC/UICC) is associated with higher mortality in patients with PC. Furthermore, a disease-free interval exceeding 36 months emerged as a relevant factor associated with improved overall survival.
- 1 January 2026
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 70 (5) , 1-8
Open AccessPrognostic factors and survival in parathyroid carcinoma: a 50-year single-center cohort study
Objective: This study aims to analyze the clinical characteristics and prognostic factors of patients with parathyroid carcinoma (PC) treated at a tertiary institution. Subjects and methods: This retrospective cohort included 30 patients with PC who were treated between 1970 and 2023 at a single reference center. Clinical, pathological, and survival data were reviewed and prognostic factors were evaluated. Results: Of the 30 cases, 16 (53.3%) were women. Mean age at diagnosis was 45.9 years, median follow-up was 60 months and mean tumor size was 33 mm. Median follow-up was 60 months. Disease recurrence occurred in 16 (53.3%) cases, with disease persistence in three (10.0%). Median disease-free survival was 80 months, with a 57% overall survival rate. Neither gender nor age showed significant impact on survival. Patients with lower-stage tumors (T1 by the AJCC/UICC and T1+T2 by the Shaha classification) had significantly better overall survival (p = 0.004 and p = 0.0018, respectively) and disease-free survival (p = 0.03 and p = 0.04, respectively) than those with more advanced stages (p = 0.03 and p = 0.04, respectively). Additionally, patients who experienced tumor recurrence after 36 months had significantly better survival outcomes than those with earlier recurrences (p = 0.02). Conclusion: Advanced tumor stage (T3 by the Shaha or T2 and above by the AJCC/UICC) is associated with higher mortality in patients with PC. Furthermore, a disease-free interval exceeding 36 months emerged as a relevant factor associated with improved overall survival.
- Open Access
- 19 December 2025
- Published by Wiley in World Journal of Surgery
- Vol. 50 (1) , 94-104
Quality of Life After Parathyroidectomy in Chronic Kidney Disease–Related Hyperparathyroidism: A Systematic Review and Meta‐Analysis
Background: Secondary and tertiary hyperparathyroidism (SHPT and THPT) are frequent complications of chronic kidney disease and kidney transplantation, often impairing quality of life (QoL) through bone pain, fatigue, and pruritus. Parathyroidectomy is the definitive treatment for refractory cases, yet its impact on patient‐reported QoL outcomes remains uncertain. Methods: We conducted a systematic review and meta‐analysis in accordance with PRISMA guidelines (PROSPERO CRD42025108038). Nine studies ( n = 675) with validated QoL assessments and ≥ 6 months of follow‐up were included. QoL was measured using SF‐36, KDQOL, and Pasieka’s parathyroid assessment of symptoms (PAS). Standardized mean differences (SMDs) were calculated, with analyses of physical (PCS) and mental (MCS) component summary scores. Meta‐regression evaluated preoperative parathyroid hormone (PTH), calcium, and phosphorus as predictors of QoL change. Results: Parathyroidectomy significantly improved global QoL (Hedges' g = 1.05; 95% CI: 0.42–1.69; p = 0.0011), PCS (SMD = 0.85; 95% CI: 0.32–1.37; p < 0.001), and MCS (SMD = 0.40; 95% CI: 0.11–0.69; p = 0.001). PAS scores also improved (SMD = −1.66; 95% CI: −2.72 to −0.60; p = 0.004). Preoperative PTH, calcium, and phosphorus were not associated with postoperative QoL gains ( p = 0.71, 0.54, 0.47). Both subtotal and total parathyroidectomy provided comparable benefits ( p = 0.76). Conclusion: Parathyroidectomy leads to meaningful QoL improvements in CKD‐related hyperparathyroidism, regardless of surgical technique. Baseline biochemical markers do not predict postoperative gains. Standardized, long‐term studies of patient‐reported outcomes are needed to guide surgical decision‐making.
- 19 December 2025
- Published by Wiley in World Journal of Surgery
- Vol. 50 (1) , 94-104
Open AccessQuality of Life After Parathyroidectomy in Chronic Kidney Disease–Related Hyperparathyroidism: A Systematic Review and Meta‐Analysis
Background: Secondary and tertiary hyperparathyroidism (SHPT and THPT) are frequent complications of chronic kidney disease and kidney transplantation, often impairing quality of life (QoL) through bone pain, fatigue, and pruritus. Parathyroidectomy is the definitive treatment for refractory cases, yet its impact on patient‐reported QoL outcomes remains uncertain. Methods: We conducted a systematic review and meta‐analysis in accordance with PRISMA guidelines (PROSPERO CRD42025108038). Nine studies ( n = 675) with validated QoL assessments and ≥ 6 months of follow‐up were included. QoL was measured using SF‐36, KDQOL, and Pasieka’s parathyroid assessment of symptoms (PAS). Standardized mean differences (SMDs) were calculated, with analyses of physical (PCS) and mental (MCS) component summary scores. Meta‐regression evaluated preoperative parathyroid hormone (PTH), calcium, and phosphorus as predictors of QoL change. Results: Parathyroidectomy significantly improved global QoL (Hedges' g = 1.05; 95% CI: 0.42–1.69; p = 0.0011), PCS (SMD = 0.85; 95% CI: 0.32–1.37; p < 0.001), and MCS (SMD = 0.40; 95% CI: 0.11–0.69; p = 0.001). PAS scores also improved (SMD = −1.66; 95% CI: −2.72 to −0.60; p = 0.004). Preoperative PTH, calcium, and phosphorus were not associated with postoperative QoL gains ( p = 0.71, 0.54, 0.47). Both subtotal and total parathyroidectomy provided comparable benefits ( p = 0.76). Conclusion: Parathyroidectomy leads to meaningful QoL improvements in CKD‐related hyperparathyroidism, regardless of surgical technique. Baseline biochemical markers do not predict postoperative gains. Standardized, long‐term studies of patient‐reported outcomes are needed to guide surgical decision‐making.
- Open Access
- 4 December 2025
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Revista de Medicina
- Vol. 104 (esp.)
Carta ao Editor - Hipoparatireoidismo após paratireoidectomia em pacientes com neoplasia endócrina múltipla tipo 1
Multiple endocrine neoplasia type 1 (MEN1) is a genetic syndrome caused by inactivation of the MEN1 tumor suppressor gene, which confers increased susceptibility to the development of neoplasms, especially endocrine tumors such as parathyroid adenomas.¹ Although it is a rare disease, primary hyperparathyroidism resulting from hyperplasia and/or neoplasia of the parathyroid glands occurs in up to 97% of individuals with the syndrome.² The treatment for hyperparathyroidism is surgical, and the two main techniques currently used are subtotal parathyroidectomy, involving the removal of 3.5 glands, and total parathyroidectomy with autotransplantation, in which all four glands are removed and a graft is prepared in the forearm.³ Although both approaches are employed, the choice of the optimal surgical technique for this condition remains under debate. A single study with a small cohort of 32 participants compared these two procedures and found no significant differences between them.⁴ The choice of surgical technique must consider the risk of recurrent hyperparathyroidism, given the multiglandular nature of the disease, and the risk of complications for example, hypoparathyroidism — defined by inappropriately low PTH levels in the presence of hypocalcemia.⁵ Traditionally, postoperative hypoparathyroidism is considered permanent when it persists for more than six months after surgery.⁶ However, this arbitrary definition is based on patients undergoing thyroidectomy and who do not have MEN1. Patients with MEN1 may have additional factors that delay the recovery of parathyroid function, such as previous malabsorptive surgeries, prolonged hungry bone syndrome, and removal of multiple glands. The latest international hypoparathyroidism guideline, published in 2022, proposed extending this limit to twelve months⁷, recognizing that functional recovery may be slower in specific contexts.
- 4 December 2025
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Revista de Medicina
- Vol. 104 (esp.)
Open AccessCarta ao Editor - Hipoparatireoidismo após paratireoidectomia em pacientes com neoplasia endócrina múltipla tipo 1
Multiple endocrine neoplasia type 1 (MEN1) is a genetic syndrome caused by inactivation of the MEN1 tumor suppressor gene, which confers increased susceptibility to the development of neoplasms, especially endocrine tumors such as parathyroid adenomas.¹ Although it is a rare disease, primary hyperparathyroidism resulting from hyperplasia and/or neoplasia of the parathyroid glands occurs in up to 97% of individuals with the syndrome.² The treatment for hyperparathyroidism is surgical, and the two main techniques currently used are subtotal parathyroidectomy, involving the removal of 3.5 glands, and total parathyroidectomy with autotransplantation, in which all four glands are removed and a graft is prepared in the forearm.³ Although both approaches are employed, the choice of the optimal surgical technique for this condition remains under debate. A single study with a small cohort of 32 participants compared these two procedures and found no significant differences between them.⁴ The choice of surgical technique must consider the risk of recurrent hyperparathyroidism, given the multiglandular nature of the disease, and the risk of complications for example, hypoparathyroidism — defined by inappropriately low PTH levels in the presence of hypocalcemia.⁵ Traditionally, postoperative hypoparathyroidism is considered permanent when it persists for more than six months after surgery.⁶ However, this arbitrary definition is based on patients undergoing thyroidectomy and who do not have MEN1. Patients with MEN1 may have additional factors that delay the recovery of parathyroid function, such as previous malabsorptive surgeries, prolonged hungry bone syndrome, and removal of multiple glands. The latest international hypoparathyroidism guideline, published in 2022, proposed extending this limit to twelve months⁷, recognizing that functional recovery may be slower in specific contexts.
- 2 September 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (1) , 291-301
Extent of Surgical Resection and Predictors of Outcomes in MEN1-related Hyperparathyroidism: A Systematic Review and Meta-analysis
Context: Primary hyperparathyroidism (PHPT) is the earliest and most frequent manifestation of multiple endocrine neoplasia type 1 (MEN1). The optimal surgical extent remains controversial due to the tradeoff between recurrence and permanent hypoparathyroidism. Objective: To evaluate outcomes of different surgical approaches in MEN1-related PHPT and assess preoperative biochemical predictors through systematic review and meta-analysis. Data Sources: MEDLINE, PubMed, Embase.com, LILACS, and CENTRAL were searched from inception to April 2025, following PRISMA guidelines (PROSPERO: CRD420251027970). Study Selection: We included studies on adult MEN1-related PHPT patients undergoing parathyroidectomy with reported recurrence, hypoparathyroidism, and preoperative biochemical data. Data Extraction: Two reviewers independently extracted data and assessed study quality. Random-effects models were used to pool risk ratios (RR) with 95% confidence intervals (CI). Meta-regression evaluated associations with preoperative PTH, calcium, and phosphorus. Data Synthesis: Thirteen studies (915 patients) were included. Less-than-subtotal parathyroidectomy (<STPT) had higher recurrence than subtotal parathyroidectomy (STPT) (RR = 1.26; 95% CI: 1.16-1.36) and total parathyroidectomy with autotransplantation (PTX) (RR = 1.35; 95% CI: 1.22-1.49). STPT showed slightly higher recurrence than PTX (RR = 1.12; 95% CI: 1.02-1.24). <STPT had lower hypoparathyroidism than STPT (RR = 0.90; 95% CI: 0.82-0.98) and PTX (RR = 0.76; 95% CI: 0.63-0.90). Grouping < STPT vs STPT/PTX confirmed higher recurrence (RR = 1.23; 95% CI: 1.03-1.46) and lower hypoparathyroidism (RR = 0.86; 95% CI: 0.78-0.96). No significant associations were found for preoperative PTH, calcium, or phosphorus with outcomes. Conclusion: Conservative surgery reduces hypoparathyroidism but increases recurrence. Personalized surgical strategies are essential in MEN1-related PHPT.
- 2 September 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (1) , 291-301
Extent of Surgical Resection and Predictors of Outcomes in MEN1-related Hyperparathyroidism: A Systematic Review and Meta-analysis
Context: Primary hyperparathyroidism (PHPT) is the earliest and most frequent manifestation of multiple endocrine neoplasia type 1 (MEN1). The optimal surgical extent remains controversial due to the tradeoff between recurrence and permanent hypoparathyroidism. Objective: To evaluate outcomes of different surgical approaches in MEN1-related PHPT and assess preoperative biochemical predictors through systematic review and meta-analysis. Data Sources: MEDLINE, PubMed, Embase.com, LILACS, and CENTRAL were searched from inception to April 2025, following PRISMA guidelines (PROSPERO: CRD420251027970). Study Selection: We included studies on adult MEN1-related PHPT patients undergoing parathyroidectomy with reported recurrence, hypoparathyroidism, and preoperative biochemical data. Data Extraction: Two reviewers independently extracted data and assessed study quality. Random-effects models were used to pool risk ratios (RR) with 95% confidence intervals (CI). Meta-regression evaluated associations with preoperative PTH, calcium, and phosphorus. Data Synthesis: Thirteen studies (915 patients) were included. Less-than-subtotal parathyroidectomy (<STPT) had higher recurrence than subtotal parathyroidectomy (STPT) (RR = 1.26; 95% CI: 1.16-1.36) and total parathyroidectomy with autotransplantation (PTX) (RR = 1.35; 95% CI: 1.22-1.49). STPT showed slightly higher recurrence than PTX (RR = 1.12; 95% CI: 1.02-1.24). <STPT had lower hypoparathyroidism than STPT (RR = 0.90; 95% CI: 0.82-0.98) and PTX (RR = 0.76; 95% CI: 0.63-0.90). Grouping < STPT vs STPT/PTX confirmed higher recurrence (RR = 1.23; 95% CI: 1.03-1.46) and lower hypoparathyroidism (RR = 0.86; 95% CI: 0.78-0.96). No significant associations were found for preoperative PTH, calcium, or phosphorus with outcomes. Conclusion: Conservative surgery reduces hypoparathyroidism but increases recurrence. Personalized surgical strategies are essential in MEN1-related PHPT.
- Open Access
Parathyroidectomy reduces the costs of medication in patients with secondary hyperparathyroidism
- Open Access
- 1 June 2024
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 46 (2)
Paratireoidectomia: ainda a melhor escolha para o tratamento do hiperparatireoidismo secundário grave
Resumo Introdução: O manejo do hiperparat-ireoidismo secundário (HPTS) é uma tarefa desafiadora com diversos fatores que contribuem para o fracasso do tratamento. A terapia calcimimética revolucionou o manejo do HPTS, levando a alterações nas indicações e no momento apropriado da paratireoidectomia (PTX) em todo o mundo. Métodos: Comparamos taxas de resposta às abordagens clínica vs. cirúrgica do HPTS em pacientes em diálise de manutenção (DRC 5D) e pacientes transplantados renais (TxR). Foi realizada uma análise retrospectiva dos achados de um ano de acompanhamento. Pacientes com DRC 5D foram divididos em 3 grupos de acordo com a estratégia de tratamento: paratireoidectomia, manejo clínico sem cinacalcete (denominado padrão - P) e com cinacalcete (P + CIN). Os pacientes com TxR foram divididos em 3 grupos: PTX, CIN (uso de cinacalcete) e observação (OBS). Resultados: Na DRC 5D, encontramos uma redução significativa do paratormônio (PTH) em todos os grupos. Apesar de todos os grupos apresentarem um PTH mais elevado no início do estudo, identificamos uma redução mais acentuada no grupo PTX. Com relação ao HPTS grave, a diferença entre os grupos foi evidentemente maior: 31%, 14% e 80% dos grupos P, P + CIN e PTX atingiram níveis adequados de PTH, respectivamente (p< 0,0001). Com relação à população TxR, embora a diferença não tenha sido tão impressionante, também foi observada uma taxa maior de sucesso no grupo PTX. Conclusão: A PTX ainda parece ser a melhor escolha de tratamento para o HPTS, especialmente em pacientes com doenças prolongadas em cenários sem recursos.
- 1 June 2024
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 46 (2)
Open AccessParatireoidectomia: ainda a melhor escolha para o tratamento do hiperparatireoidismo secundário grave
Resumo Introdução: O manejo do hiperparat-ireoidismo secundário (HPTS) é uma tarefa desafiadora com diversos fatores que contribuem para o fracasso do tratamento. A terapia calcimimética revolucionou o manejo do HPTS, levando a alterações nas indicações e no momento apropriado da paratireoidectomia (PTX) em todo o mundo. Métodos: Comparamos taxas de resposta às abordagens clínica vs. cirúrgica do HPTS em pacientes em diálise de manutenção (DRC 5D) e pacientes transplantados renais (TxR). Foi realizada uma análise retrospectiva dos achados de um ano de acompanhamento. Pacientes com DRC 5D foram divididos em 3 grupos de acordo com a estratégia de tratamento: paratireoidectomia, manejo clínico sem cinacalcete (denominado padrão - P) e com cinacalcete (P + CIN). Os pacientes com TxR foram divididos em 3 grupos: PTX, CIN (uso de cinacalcete) e observação (OBS). Resultados: Na DRC 5D, encontramos uma redução significativa do paratormônio (PTH) em todos os grupos. Apesar de todos os grupos apresentarem um PTH mais elevado no início do estudo, identificamos uma redução mais acentuada no grupo PTX. Com relação ao HPTS grave, a diferença entre os grupos foi evidentemente maior: 31%, 14% e 80% dos grupos P, P + CIN e PTX atingiram níveis adequados de PTH, respectivamente (p< 0,0001). Com relação à população TxR, embora a diferença não tenha sido tão impressionante, também foi observada uma taxa maior de sucesso no grupo PTX. Conclusão: A PTX ainda parece ser a melhor escolha de tratamento para o HPTS, especialmente em pacientes com doenças prolongadas em cenários sem recursos.
- Open Access
- 1 June 2024
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 46 (2) , e20230024
Parathyroidectomy: still the best choice for the management of severe secondary hyperparathyroidism
Introduction: Management of secondary hyperparathyroidism (SHPT) is a challenging endeavor with several factors contruibuting to treatment failure. Calcimimetic therapy has revolutionized the management of SHPT, leading to changes in indications and appropriate timing of parathyroidectomy (PTX) around the world. Methods: We compared response rates to clinical vs. surgical approaches to SHPT in patients on maintenance dialysis (CKD 5D) and in kidney transplant patients (Ktx). A retrospective analysis of the one-year follow-up findings was carried out. CKD 5D patients were divided into 3 groups according to treatment strategy: parathyroidectomy, clinical management without cinacalcet (named standard - STD) and with cinacalcet (STD + CIN). Ktx patients were divided into 3 groups: PTX, CIN (cinacalcet use), and observation (OBS). Results: In CKD 5D we found a significant parathormone (PTH) decrease in all groups. Despite all groups had a higher PTH at baseline, we identified a more pronounced reduction in the PTX group. Regarding severe SHPT, the difference among groups was evidently wider: 31%, 14% and 80% of STD, STD + CIN, and PTX groups reached adequate PTH levels, respectively (p<0.0001). Concerning the Ktx population, although the difference was not so impressive, a higher rate of success in the PTX group was also observed. Conclusion: PTX still seems to be the best treatment choice for SHPT, especially in patients with prolonged diseases in unresourceful scenarios.
- 1 June 2024
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 46 (2) , e20230024
Open AccessParathyroidectomy: still the best choice for the management of severe secondary hyperparathyroidism
Introduction: Management of secondary hyperparathyroidism (SHPT) is a challenging endeavor with several factors contruibuting to treatment failure. Calcimimetic therapy has revolutionized the management of SHPT, leading to changes in indications and appropriate timing of parathyroidectomy (PTX) around the world. Methods: We compared response rates to clinical vs. surgical approaches to SHPT in patients on maintenance dialysis (CKD 5D) and in kidney transplant patients (Ktx). A retrospective analysis of the one-year follow-up findings was carried out. CKD 5D patients were divided into 3 groups according to treatment strategy: parathyroidectomy, clinical management without cinacalcet (named standard - STD) and with cinacalcet (STD + CIN). Ktx patients were divided into 3 groups: PTX, CIN (cinacalcet use), and observation (OBS). Results: In CKD 5D we found a significant parathormone (PTH) decrease in all groups. Despite all groups had a higher PTH at baseline, we identified a more pronounced reduction in the PTX group. Regarding severe SHPT, the difference among groups was evidently wider: 31%, 14% and 80% of STD, STD + CIN, and PTX groups reached adequate PTH levels, respectively (p<0.0001). Concerning the Ktx population, although the difference was not so impressive, a higher rate of success in the PTX group was also observed. Conclusion: PTX still seems to be the best treatment choice for SHPT, especially in patients with prolonged diseases in unresourceful scenarios.
- Open Access
- 1 June 2022
- Published by Bioscientifica in Endocrine Connections
- Vol. 11 (6)
Impact of parathyroidectomy on quality of life in multiple endocrine neoplasia type 1
Background: Potential influences of parathyroidectomy (PTx) on the quality of life (QoL) in multiple endocrine neoplasia type 1-related primary hyperparathyroidism (HPT/MEN1) are unknown. Method: Short Form 36 Health Survey Questionnaire was prospectively applied to 30 HPT/MEN1 patients submitted to PTx (20, subtotal; 10, total with autograft) before, 6 and 12 months after surgery. Parameters that were analyzed included QoL, age, HPT-related symptoms, general pain, comorbidities, biochemical/hormonal response, PTx type and parathyroid volume. Results: Asymptomatic patients were younger (30 vs 38 years; P = 0.04) and presented higher QoL scores than symptomatic ones: Physical Component Summary score (PCS) 92.5 vs 61.2, P = 0.0051; Mental Component Summary score (MCS) 82.0 vs 56.0, P = 0.04. In both groups, QoL remained stable 1 year after PTx, independently of the number of comorbidities. Preoperative general pain was negatively correlated with PCS (r = −0.60, P = 0.0004) and MCS (r = −0.57, P = 0.0009). Also, moderate/intense pain was progressively (6/12 months) more frequent in cases developing hypoparathyroidism. The PTx type and hypoparathyroidism did not affect the QoL at 12 months although remnant parathyroid tissue volume did have a positive correlation (P = 0.0490; r = 0.3625) to PCS 12 months after surgery. Patients with one to two comorbidities had as pre-PTx PCS (P = 0.0015) as 12 months and post-PTx PCS (P = 0.0031) and MCS (P = 0.0365) better than patients with three to four comorbidities. Conclusion: A variable QoL profile was underscored in HPT/MEN1 reflecting multiple factors associated with this complex disorder as comorbidities, advanced age at PTx and presence of preoperative symptoms or of general pain perception. Our data encourage the early indication of PTx in HPT/MEN1 by providing known metabolic benefits to target organs and avoiding potential negative impact on QoL.
- 1 June 2022
- Published by Bioscientifica in Endocrine Connections
- Vol. 11 (6)
Open AccessImpact of parathyroidectomy on quality of life in multiple endocrine neoplasia type 1
Background: Potential influences of parathyroidectomy (PTx) on the quality of life (QoL) in multiple endocrine neoplasia type 1-related primary hyperparathyroidism (HPT/MEN1) are unknown. Method: Short Form 36 Health Survey Questionnaire was prospectively applied to 30 HPT/MEN1 patients submitted to PTx (20, subtotal; 10, total with autograft) before, 6 and 12 months after surgery. Parameters that were analyzed included QoL, age, HPT-related symptoms, general pain, comorbidities, biochemical/hormonal response, PTx type and parathyroid volume. Results: Asymptomatic patients were younger (30 vs 38 years; P = 0.04) and presented higher QoL scores than symptomatic ones: Physical Component Summary score (PCS) 92.5 vs 61.2, P = 0.0051; Mental Component Summary score (MCS) 82.0 vs 56.0, P = 0.04. In both groups, QoL remained stable 1 year after PTx, independently of the number of comorbidities. Preoperative general pain was negatively correlated with PCS (r = −0.60, P = 0.0004) and MCS (r = −0.57, P = 0.0009). Also, moderate/intense pain was progressively (6/12 months) more frequent in cases developing hypoparathyroidism. The PTx type and hypoparathyroidism did not affect the QoL at 12 months although remnant parathyroid tissue volume did have a positive correlation (P = 0.0490; r = 0.3625) to PCS 12 months after surgery. Patients with one to two comorbidities had as pre-PTx PCS (P = 0.0015) as 12 months and post-PTx PCS (P = 0.0031) and MCS (P = 0.0365) better than patients with three to four comorbidities. Conclusion: A variable QoL profile was underscored in HPT/MEN1 reflecting multiple factors associated with this complex disorder as comorbidities, advanced age at PTx and presence of preoperative symptoms or of general pain perception. Our data encourage the early indication of PTx in HPT/MEN1 by providing known metabolic benefits to target organs and avoiding potential negative impact on QoL.
- 20 September 2021
- Published by Wiley in Head & Neck
- Vol. 43 (12) , 3996-4009
Primary hyperparathyroidism: Disease of diverse genetic, symptomatic, and biochemical phenotypes
Genetic, symptomatic, and biochemical heterogeneity of patients with primary hyperparathyroidism (PHPT) has become apparent in recent years. An in‐depth, evidence‐based review of the phenotypes of PHPT was conducted. This review was intended to provide the resulting information to surgeons who operate on patients with hyperparathyroidism. This review revealed that the once relatively clear distinction between familial and sporadic PHPT has become more challenging by the finding of various germline mutations in patients with seemingly sporadic PHPT. On the one hand, the genetic and clinical characteristics of some syndromes in which PHPT is an important component are now better understood. On the other hand, knowledge is emerging about novel syndromes, such as the rare multiple endocrine neoplasia type IV (MEN4), in which PHPT occurs frequently. It also revealed that, currently, the classical array of symptoms of PHPT is seen rarely upon initial presentation for evaluation. More common are nonspecific, nonclassical symptoms and signs of PHPT. In areas of the world where serum calcium levels are checked routinely, most patients today are “asymptomatic” and they are diagnosed after an incidental finding of hypercalcemia; however, some of them have subclinical involvement of bones and kidneys, which is demonstrated on radiographs, ultrasound, and modern imaging techniques. Last, the review points out that there are three distinct biochemical phenotypes of PHPT. The classical phenotype in which calcium and parathyroid hormone levels are both elevated, and other disease presentations in which the serum levels of calcium or intact parathyroid hormone are normal. Today several, distinct phenotypes of the disease can be identified, and they have implications in the diagnostic evaluation and treatment of patients, as well as possible screening of relatives.
- 20 September 2021
- Published by Wiley in Head & Neck
- Vol. 43 (12) , 3996-4009
Primary hyperparathyroidism: Disease of diverse genetic, symptomatic, and biochemical phenotypes
Genetic, symptomatic, and biochemical heterogeneity of patients with primary hyperparathyroidism (PHPT) has become apparent in recent years. An in‐depth, evidence‐based review of the phenotypes of PHPT was conducted. This review was intended to provide the resulting information to surgeons who operate on patients with hyperparathyroidism. This review revealed that the once relatively clear distinction between familial and sporadic PHPT has become more challenging by the finding of various germline mutations in patients with seemingly sporadic PHPT. On the one hand, the genetic and clinical characteristics of some syndromes in which PHPT is an important component are now better understood. On the other hand, knowledge is emerging about novel syndromes, such as the rare multiple endocrine neoplasia type IV (MEN4), in which PHPT occurs frequently. It also revealed that, currently, the classical array of symptoms of PHPT is seen rarely upon initial presentation for evaluation. More common are nonspecific, nonclassical symptoms and signs of PHPT. In areas of the world where serum calcium levels are checked routinely, most patients today are “asymptomatic” and they are diagnosed after an incidental finding of hypercalcemia; however, some of them have subclinical involvement of bones and kidneys, which is demonstrated on radiographs, ultrasound, and modern imaging techniques. Last, the review points out that there are three distinct biochemical phenotypes of PHPT. The classical phenotype in which calcium and parathyroid hormone levels are both elevated, and other disease presentations in which the serum levels of calcium or intact parathyroid hormone are normal. Today several, distinct phenotypes of the disease can be identified, and they have implications in the diagnostic evaluation and treatment of patients, as well as possible screening of relatives.
- Open Access
- 1 June 2021
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 43 (2) , 228-235
Delayed sampling of intraoperative parathormone may be unnecessary during parathyroidectomy in kidney-transplanted and dialysis patients
Introduction: Some authors advise in favor of delayed sampling of intraoperative parathormone testing (ioPTH) during parathyroidectomy in dialysis and kidney-transplanted patients. The aim of the present study was to evaluate the intensity and the role of delayed sampling in the interpretation of ioPTH during parathyroidectomy in dialysis patients (2HPT) and successful kidney-transplanted patients (3HPT) compared to those in single parathyroid adenoma patients (1HPT). Methods: This was a retrospective study of ioPTH profiles in patients with 1HPT, 2HPT, and 3HPT operated on in a single institution. Samples were taken at baseline ioPTH (sampling at the beginning of the operation), ioPTH-10 min (10 minutes after excision of the parathyroid glands), and ioPTH-15 min (15 minutes after excision of the parathyroid glands). The values were compared to baseline. Results: Median percentage values of ioPTH compared to baseline (100%) were as follows: 1HPT, ioPTH-10 min = 20% and ioPTH-15 min = 16%; 2HPT, ioPTH-10 min = 14% and ioPTH-15 min = 12%; 3HPT, ioPTH-10 min = 18% and ioPTH-15 min = 15%. Discussion: The reduction was equally effective at 10 minutes in all groups. In successful cases, ioPTH decreases satisfactorily 10 minutes after parathyroid glands excision in dialysis and transplanted patients, despite significant differences in kidney function. The postponed sampling of ioPTH appears to be unnecessary.
- 1 June 2021
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 43 (2) , 228-235
Open AccessDelayed sampling of intraoperative parathormone may be unnecessary during parathyroidectomy in kidney-transplanted and dialysis patients
Introduction: Some authors advise in favor of delayed sampling of intraoperative parathormone testing (ioPTH) during parathyroidectomy in dialysis and kidney-transplanted patients. The aim of the present study was to evaluate the intensity and the role of delayed sampling in the interpretation of ioPTH during parathyroidectomy in dialysis patients (2HPT) and successful kidney-transplanted patients (3HPT) compared to those in single parathyroid adenoma patients (1HPT). Methods: This was a retrospective study of ioPTH profiles in patients with 1HPT, 2HPT, and 3HPT operated on in a single institution. Samples were taken at baseline ioPTH (sampling at the beginning of the operation), ioPTH-10 min (10 minutes after excision of the parathyroid glands), and ioPTH-15 min (15 minutes after excision of the parathyroid glands). The values were compared to baseline. Results: Median percentage values of ioPTH compared to baseline (100%) were as follows: 1HPT, ioPTH-10 min = 20% and ioPTH-15 min = 16%; 2HPT, ioPTH-10 min = 14% and ioPTH-15 min = 12%; 3HPT, ioPTH-10 min = 18% and ioPTH-15 min = 15%. Discussion: The reduction was equally effective at 10 minutes in all groups. In successful cases, ioPTH decreases satisfactorily 10 minutes after parathyroid glands excision in dialysis and transplanted patients, despite significant differences in kidney function. The postponed sampling of ioPTH appears to be unnecessary.